Overexpression of cyclooxygenase-2 in non-small cell lung cancer

Respiratory Medicine

Volumn 98, Issue 2, 2004, Pages 164-172

  Petkova, D K ^a   Clelland, C ^a   Ronan, J ^a   Pang, L ^a   Coulson, J M ^a   Lewis, S ^a   Knox, Alan J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cyclooxygenase; Immunohistochemistry; Lung cancer; Lung cancer cell lines

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BRONCHODILATING AGENT; CELECOXIB; CYCLOOXYGENASE 2; ISOENZYME; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CELL CULTURE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ALVEOLUS EPITHELIUM; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG RESECTION; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

EID: 0842345466     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.09.006     Document Type: Article

References (51)

1. Kim ES, Hong WK, Khuri FR. Prevention of lung cancer. The new millennium. Chest Surg Clin North Am 2000;10(4): 663-90.
2. Cancer facts and Figures 2000. American Cancer Society 2000 Atlanta, GA, http://www.cancer.org/dowloads/STT/F&F00.pdf.
3. Sjodahl R. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Extent, mode, and dose dependence of anticancer effects. Am J Med 2001;110(1A):66S-9S.
4. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7(4):861-7.
5. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
6. Sano H, Kuwahito Y, Wilder RL, Hashiramoto A, et al. Expression of cyclooxygenase-1 and 2 in human colorectal cancer. Cancer Res 1995;55:3785-9.
7. Zimmermann KC, Sarbia M, Weber AA, Brochard F, Gabbert HE, Schror K. Cyclooxygenase expression in human oesophageal carcinoma. Cancer Res 1999;59:198-204.
8. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
9. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-4.
10. Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumours. Cancer 2000;89(12):2637-45.
11. Yoshimatsu K, Altorki NK, Golijanin D, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001;7(9):2669-74.
12. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58(22):4997-5001.
13. Hosomi Y, Yokose T, Hirose Y, et al. Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000;30(2):73-81.
14. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997;100(6):1325-9.
15. Thun MJ. Aspirin, NSAIDs, and digestive tract cancers. Cancer Metastasis Rev 1994;13:269-77.
16. International Agency for Research on Cancer (IARC). Aspirin. In: IARC Handbooks on Cancer Prevention. 1. Non-steroidal anti-inflammatory drugs 1997;1:43-90.
17. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
18. Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996;222:179-88.
19. Giardiello FM, Offerhaus GJ, DuBois RN. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 1995;31A:1071-6.
20. Harris RE, Namboodiri KK, Farrar WB. Non-steroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996;7: 203-5.
21. Castonguay A, Rioux N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis 1997;18(3):491-6.
22. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn Jr. PA, Chou TC. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 1999;59(24):6178-84.
23. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 1993;328:1313-6.
24. Eli Y, Przedecki F, Levin G, Kariv N, Raz A. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumour cells grown in vitro and in vivo. Bioc Pharmacol 2001;61(5):565-71.
25. Moody TW, Leyton J, Zakowicz H, et al. Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res 2001;21(3B):1749-55.
26. Tomozawa S, Nagawa H, Tsuno N, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Brit J Cancer 1999;81(8): 1274-9.
27. Morecki S, Yacovlev E, Gelfand Y, Trembovler V, Shohami E, Slavin S. Induction of antitumour immunity by indomethacin. Cancer Immunol, Immunother 2000;48(11):613-20.
28. Levin G, Kariv N, Khomiak E, Raz A. Indomethacin inhibits the accumulation of tumour cells in mouse lungs and subsequent growth of lung metastases. Chemotherapy 2000;46(6):429-37.
29. Khoo NK, Chan FP, Saarloos MN, Lala PK. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclooxygenase inhibitors alone or in combination with IL-2. Clin Exp Metastasis 1992;10(4):239-45.
30. Yao R, Rioux N, Castonguay A, You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumourigenesis. Exp Lung Res 2000;26(8): 731-42.
31. Tsubouchi Y, Mukai S, Kawahito Y, et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000;20(5A):2867-72.
32. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60(5):1306-11.
33. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
34. Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res 1999;90(12):1338-43.
35. Watkins DN, Lenzo JC, Segal A, Garlepp MJ, Thompson PJ. Expression and localization of cyclooxygenase isoforms in non-small cell lung cancer. Eur Respir J 1999;14(2):412-8.
36. Hasturk S, Kemp B, Kalapurakal S, Hong W, Lee J. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer 2002;94(4):1023-31.
37. Petkova DK, Pang L, Range SR, Holland E, Knox AJ. Immunocytochemical localization of cyclooxygenase isoforms in cultured human airway structural cells. Clin Exp Allergy 1999;29:965-72.
38. Pang L, Knox AJ. Effect of interleukin-1β, tumour necrosis factor-α and interferon-γ on the induction of cyclooxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 1997;121:579-87.
39. Petkova DK, Clelland CA, Ronan JE, Lewis S, Knox AJ. Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis. Histopathology 2003; 43(4):381-6.
40. Lechner JF, Haugen A, McClendon IA, Pettis EW. Clonal growth of normal adult human bronchial epithelial cells in a serum-free medium. In vitro J Tiss Cul Assoc 1982;18: 633-42.
41. 2 release by bradykinin in human airway smooth muscle cells: involvement of COX-2 induction. Am J Physiol 1997;273:L1132-40.
42. Baillie-Johnson H, Twentyman PR, Fox NE. Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer 1985;52(4):495-504.
43. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58(17): 3761-4.
44. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5(5):1001-5.
45. Mestre JR, Chan G, Zhang F, et al. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann NY Acad Sci 1999;889:62-71.
46. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19(5): 723-9.
47. Sales KJ, Katz AA, Davis M, et al. Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 2001;86(5):2243-9.
48. Shirahama T, Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7(3):558-61.
49. Bauer AK, Dwyer-Nield LD, Malkinson AM. High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumours. Carcinogenesis 2000;21(4):543-50.
50. Young MR, Young ME, Wepsic HT. Effect of prostaglandin E2-producing nonmetastatic Lewis lung carcinoma cells on the migration of prostaglandin E2-responsive metastatic Lewis lung carcinoma cells. Cancer Res 1987;47(14):3679-83.
51. Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL. Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 2002;112(2): 238-42.